Houlihan Lokey Advises GenesisCare UK

Houlihan Lokey is pleased to announce that GenesisCare UK (the Company) has successfully arranged a term debt raise to refinance its existing indebtedness and has raised committed growth financing and working capital lines. Houlihan Lokey served as the exclusive financing advisor to the Company. The transaction signed in December 2024 and is expected to close in January 2025.

GenesisCare UK is the U.K.’s leading cancer care provider, transforming cancer care with advanced diagnostics, medical oncology, radiotherapy, and theranostics. Operating 14 specialist outpatient centres, the company provides patients with a world-class standard of care and access to the latest innovative treatments proven to be safe and effective, delivered by highly trained physicians and healthcare professionals.

With a philosophy to treat the whole patient, not just the cancer, GenesisCare UK takes an integrated cancer care approach. Its personalised treatment programmes are supported with wellbeing services delivered through its unique partnership with the charity Penny Brohn UK. The Company also provides exercise medicine, which is proven to deliver improved patient outcomes. In addition, it works with universities and leading clinicians around the world to research and design new and better ways to treat cancers and has a growing U.K. clinical trials programme to support bringing new therapies to more patients. Treatments are available for patients with health insurance and those paying for their own care.

RELATED: Healthcare, Capital Markets